Ijzer (Iii)carboxymaltose Viatris (Iron)

Ijzer (III)carboxymaltose Viatris is used to correct iron deficiency anemia across several clinical settings.

• Iron deficiency anemia: restores hemoglobin levels and replenishes depleted iron stores.
• Iron deficiency anemia in chronic kidney disease: supports erythropoiesis when oral iron is ineffective.
• Iron deficiency anemia in perioperative patients: provides rapid iron repletion before surgery to reduce transfusion needs.

• Ferric carboxymaltose delivers a stable iron-carbohydrate complex that releases elemental iron in a controlled manner after intravenous administration. The iron is taken up by reticuloendothelial cells, transferred to transferrin, and incorporated into hemoglobin within developing red blood cells, thereby correcting iron deficiency and supporting normal erythropoiesis.

Adverse reactions may occur following intravenous administration of ferric carboxymaltose.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Headache: transient cranial discomfort.
• Injection site pain: local tenderness or erythema.
• Transient hypotension: brief drop in blood pressure during infusion.
• Metallic taste: temporary alteration of taste perception.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe hypotension: marked blood pressure decline possibly leading to syncope.
• Hypophosphatemia: significant drop in serum phosphate levels.
• Acute respiratory distress: sudden breathing difficulty.
• Severe skin reactions: such as Stevens‑Johnson syndrome.

Use of ferric carboxymaltose requires careful clinical assessment and monitoring.

• Baseline assessment: confirm iron deficiency with laboratory tests before administration.
• Hemoglobin monitoring: check levels periodically to avoid excessive iron loading.
• Hypersensitivity caution: avoid in patients with known allergy to ferric carboxymaltose or other IV iron products.
• Infusion rate: administer at recommended rate to reduce risk of hypotension.
• Phosphate monitoring: observe serum phosphate during and after treatment.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ferric carboxymaltose may interact with other medications, affecting safety or efficacy.

Major Interactions (Avoid)

• Concurrent IV iron products: risk of iron overload.
• Known hypersensitivity to ferric carboxymaltose: may trigger severe allergic reactions.
• Parenteral iron dextran: combined use can increase toxicity.

Moderate Interactions (Monitor Closely)

• Oral iron supplements: may reduce absorption of each other; stagger dosing.
• Erythropoiesis‑stimulating agents: enhanced hematologic response, monitor hemoglobin.
• Tetracycline antibiotics: possible chelation reducing antibiotic effectiveness.
• Phosphate binders: may exacerbate hypophosphatemia.
• Antihypertensive drugs: monitor blood pressure due to potential hypotensive effect.